But if they're not able to do it, how do they do a lot of it?

Well, so for people who are sequencing a lot of plasmids, right? But they just weren't using Nanopore for that, and so the point is like this is a thing that it would be better.

Like, new things were enabled when we launched whole plasmid sequencing.

There was a number of new things that were, that were launched, and it's sort of like once you've done that, once you've got burned and realized, "Oh, I was being misled by the Sanger data in a way that was affecting my research," you're never gonna use that again, right? So, and you can just look at what that market is and how people are, are generating plasmids.

Um, and so, you know, for, for a while when I would think about this stuff, it's, you know, I don't know if other people could have thought about doing the business that we did.

I certainly have talked to a lot of people that say like, "Oh, I was gonna do that." Um, they didn't do it.

Um, but like, "Oh yeah, I, I was thinking about that." Um, we focused very...

Mm-hmm